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Excess glucose – hyperglycemia – has
long been associated with type 2 diabetes.
Ancient literature from Egypt and India
describe the disease; it was easily identi-
fiable because “a patient’s urine attracted
ants” (1). More than two millennia later,
monitoring glycemic status continues to be
central to clinical management. It is cur-
rently the only variable accepted for stan-
dardization of both diagnosis as well as
treatment (2). Despite its strong associa-
tion with diabetes, however, hyperglycemia
is not the disease per se. It is important to
ask what other variables besides glucose are
relevant to the disorder.
In particular, it would be very useful to
discover covariates of glucose that can help
predict patient recovery on anti-diabetic
treatment. The recognition that medical
care needs to be personalized – since indi-
vidual responses to anti-diabetic treatment
vary with patient pathophysiology – is rela-
tively recent. The American Diabetes Asso-
ciation, for example, now recommends that
targets of glycemic control be selected indi-
vidually, not uniformly (3). Raz et al. point
to the need for data that can help identify
what characteristics of patients determine
how well they respond to specific treat-
ments (4). Research seeking covariates of
glucose in diabetes is, in fact, not new; it
has been ongoing for a very long time. Dif-
ferent disease models exist, and they vary
in emphasis on what factor is thought to
be of causal importance. From an etio-
logical viewpoint, increased insulin resis-
tance (IR) and inadequate beta-cell secre-
tion are responsible for the development
of overt hyperglycemia. In epidemiologi-
cal terms, environment factors – increased
pesticides, hormones and drugs in agri-
culture, farm animals, and food (5), or
altered social behavior (6) – may be respon-
sible for its increased incidence in recent
decades. In the absence of sufficient data,
however, one focuses – prudently – on
the metabolic view of glucose imbalance.
Two physiological theories are center-stage
here, differing in the emphasis they place
on the key defect underlying the disrup-
tion of energy homeostasis. The consensus
model is that diabetes is obesity-linked:
nutritional excess coupled to a sedentary
lifestyle leads to increases in circulating
lipids and cytokines; from this follows the
inference that inflammation is the driver
of IR, and subsequently, hyperinsulinemia.
An alternate model (5) emphasizes the cen-
tral defect is hypersecretion; in this view,
hyperinsulinemia is the cause, and IR is a
compensatory adaptation. And yet, neither
theory has yielded a satisfactory covariate
of monitoring diabetes apart from glucose.
Oxidative stress (OS) and antioxidant
status are potent indicators of glucose
metabolism; biomarkers of OS are well
known to show strong correlation with
glycemic status. Because reactive oxygen
species (ROS) are naturally produced in
respiration, it is not surprising that ROS
are also a significant energy signal of the
cell. OS – the unbalanced, excess accumu-
lation of ROS – features prominently in all
integrative theories of glucose dysregula-
tion in diabetes. This immediately suggests
that OS is potentially a major covariate
of glucose. The difficulty has been that
hyperglycemia is typically thought to cause
OS, not the other way around. The theory
is that hyperglycemia arises first, causes
OS, and over time this results in diabetic
complications (7–9). There is converg-
ing evidence now, however, that OS plays
a major role in the development of dia-
betes as well. In the beta-cell, glucose
uptake is transduced through ROS into
signals that modulate secretion (10, 11). In
peripheral tissue – liver, muscle, and adi-
pose – there are compelling experiments to
postulate that ROS could be the common
signal whereby changes in IR are exercised
(12–14). In other words, OS is central to
the mechanisms that exacerbate the dia-
betic condition. Recently, James Watson
has proposed a striking new hypothesis
that stresses the redox origins of diabetes
(15), albeit for very different reasons. His
claim is the roots of diabetes lie in a lack
of exercise, and an insufficiently oxidant
endoplasmic reticulum (ER) environment
that leads to a misfolded insulin response.
We argue that – such controversy notwith-
standing – both theoretical considerations
as well as experimental evidence point to
the possibility that OS is an important
covariate of glucose in the development of
hyperglycemia, and hence also in recovery
during anti-diabetic treatment.
The role of OS in anti-diabetic treat-
ment does not seem to have been fully
appreciated yet. On the one hand, antiox-
idants are currently not recommended
practice in anti-diabetic therapy, because
their efficacy is not established, and there
could even be harm in their long-term use
(2). On the other hand, diabetic patients,
whose glucose is controlled by drug ther-
apy, show a concomitant improvement
in OS: as glycemic pressure is relieved,
antioxidant defense relieves OS. We have
www.frontiersin.org June 2014 | Volume 5 | Article 89 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kulkarni et al. Oxidative stress influences diabetes therapy
shown, for example, OS in newly diagnosed
Indian diabetic patients is alleviated over
the first 8 weeks of starting anti-diabetic
treatment (16). Over 12 different biomark-
ers of OS – various antioxidant enzymes
and molecules, and damage markers –
were studied; each one decreased sig-
nificantly with decreasing glucose within
2 months. These observations raise the fol-
lowing interesting possibility: does antiox-
idant defense capacity influence the effi-
ciency of treatment in controlling glucose?
In other words, how might OS status co-
determine recovery from glycemic stress in
anti-diabetic treatment.
The covariate character of OS is, indeed,
revealed in a reexamination of data just
alluded to. We adapted the data in Ref.
(16) to compute an 8-week average rate
of glucose restoration (RR) relative to the
cellular antioxidant glutathione (GSH). We
and others (17) have found hematologic
GSH to be an excellent reporter of OS in
diabetic patients. We find that RR varies
not only with the A1C value prior to
treatment but also the pre-treatment GSH
level (Figure 1): a multiple linear regres-
sion analysis of RR with respect to 0-
week A1C, GSH, and age confirms a sig-
nificant dependence on both 0-week A1C
(coefficient: −1.23; p-value: <0.001) and
GSH (coefficient: 0.33; p-value: 0.006),
but not age (coefficient: −0.006; p-value:
0.65; R2= 0.80 after removing two out-
liers). This implies that OS and the antiox-
idant defense status at the time of start-
ing treatment feature prominently in how
well glucose control takes in subsequent
therapy. The parsimonious explanation is:
RR follows first-order kinetics with respect
to 0-week A1C, and, the greater the antiox-
idant defense prior to therapy is, the better
is the recovery rate (RR). That is, anti-
diabetic treatment is more effective when
the body’s innate defense to OS is high.
These were results of a pilot study – the
study size was small, and only intensive
periods of glucose control were examined –
and are therefore prospective in nature.
Although these observations are tantaliz-
ing, considerable future work needs to be
done to substantiate them in greater detail.
A theory is sorely needed to understand
these observations. Are there reasons to
expect that OS might be a covariate of RR
more generally? Clearly, a large component
of ROS and OS is closely tied into glucose.
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FIGURE 1 | Improvement rates of A1C in newly diagnosed diabetics over
a treatment period of 8weeks are correlated with initial A1C and GSH.
n=44; BMI<30 with mean and standard deviation (25.8±3.6); age between
18 and 65 years (45.2±7.9). (A) A1C decreases consistently with treatment
over 2 months. An average recovery rate (RR) is computed as (8-week
A1C – 0-week A1C). (B) A normal Q–Q plot reveals two outliers, Cases 12 and
21. RR varies with (C) 0-week A1C, and (D) 0-week GSH. A multiple linear
regression analysis of RR with respect to 0-week A1C, GSH and age is
described in the text. Data collection is described in Ref. (16); outliers were
removed, and A1C and GSH were normalized as z -scores in the analysis.
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However, it is important to note that GSH
is a predictor of RR independently of glu-
cose as well. What these results suggest is
that OS has character beyond simply being
slaved to glucose. Theoretically, there can
be two kinds of reasons to expect that OS
asserts a glucose-independent control on
RR. One, OS is influenced by nutrient fac-
tors other than glucose: fatty acids and
other molecules – saccharides, for exam-
ple – are stressors of OS as well, and directly
stimulate secretion. During the develop-
ment of IR as well, OS is a locus of insults
arising not only from glucose but also
fatty acids and inflammation (12). Thus,
glucose-independent changes in OS can
potentially influence rates of restoration
of glucose homeostasis. The other rea-
son might be: glucose-dependent changes
in OS might potentially feed back onto
RR. This argument is somewhat delicate,
and requires noting that the physiologi-
cal processes involved in glucose home-
ostasis are likely to be non-linear in gen-
eral. Consider a potential scenario how
this might occur: an initial change in glu-
cose induced by drugs will relieve OS in
beta-cells; if this results in an improvement
in secretion that is supralinear, i.e., more
than a simple compensatory response, it
would, in turn, relieve hyperglycemia fur-
ther. In other words, local non-linearities
may result in changes that are no longer
linear at the systemic level; hence, it need
not be surprising if OS facilitates a pos-
itive cycle, potentiating the effectiveness
of a drug. To study this further, systemic
models of glucose homeostasis [such as
Homeostasis Model Assessment (HOMA)
(18)] will need to incorporate OS in the
future.
Finally, is the covariate nature of oxi-
dant stress in determining recovery con-
gruent with the Watson hypothesis? Exer-
cise is undoubtedly a major component of
anti-diabetic therapy. The paradox seems
to be that exercise raises a ROS load and
further stresses OS. However, given that
the benefits of exercise are numerous, its
effects seem to be beneficial rather than
deleterious in a final sum. In terms of the
data in Figure 1: the greater the antioxi-
dant defense of the body, the greater would
be the ability to tolerate an exercise-related
OS effect, and the faster would be the rate
of recovery. However, the Watson hypoth-
esis does point to a need to better weigh in
a compartmentalized nature of OS: Local
redox action may at times run counter to
the global, integrated effects of oxidative
action.
If OS is a covariate of recovery, mea-
suring OS concurrently with glucose can
be useful clinically. Measures of OS carry
diagnostic information that can be used
to supplement a glucose-based program of
treatment. We are currently investigating
how measuring GSH along with A1C might
better select targets of glycemic control
(manuscript communicated).
Redox function and OS seem poised
for a renewed surge of interest in diabetes
research. Interest in OS in diabetes is now
stretching beyond its role only in the devel-
opment of complications. Though there is
much that we do not yet understand about
its primary role in the development of the
disorder and its treatment, this much is
clear: diabetes is unmistakably recogniz-
able as a redox disease. Future research is
likely to unveil not only new treatments
based on the control of oxidant stress but,
perhaps, the prevention of diabetes as well.
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